trending Market Intelligence /marketintelligence/en/news-insights/trending/Oh_ATnrUgxtbKH1a5DBDrw2 content esgSubNav
In This List

ADMA shareholders approve asset acquisition from Biotest

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


ADMA shareholders approve asset acquisition from Biotest

ADMA Biologics Inc. shareholders approved the company's planned acquisition of certain assets from Biotest Pharmaceuticals Corp.

The assets include facilities and certain Biotest employees in Boca Raton, Fla., a U.S. Food and Drug Administration-licensed product portfolio including Nabi-HB and Bivigam, and contract manufacturing and services agreement for a third party's licensed hyperimmune globulin product.

The acquisition is expected to close in June.

Biotest Pharmaceuticals is a wholly owned subsidiary of Biotest AG.